Searchable abstracts of presentations at key conferences in endocrinology

ea0021p285 | Pituitary | SFEBES2009

Electrocardiographic features in Cushing’s disease: are there specific EKG changes associated with hypercortisolemia?

Alexandraki Krystallenia , Kaltsas Gregory , Vouliotis Apostolos , Papaioannou Theodoros , Apostolopoulos Nikolaos , Trisk Lauren , Zilos Athanasios , Akker Scott , Chew Shern , Drake William , Anastasakis Aris , Grossman Ashley

Introduction: Hypercortisolaemia is characterised by an increased risk of cardiovascular disease (CVD), either through a direct action on the myocardium or by affecting traditional cardiovascular risk factors. The electrocardiogram (ECG) is the initial examination to assess the structural and functional characteristics of the myocardium.Aim of the study: To investigate whether the metabolic and cardiovascular features of Cushing’s disease (CD) are a...

ea0016p478 | Neuroendocrinology | ECE2008

Cyclical Cushing's syndrome: prevalence in patients with Cushing's disease

Alexandraki Krystallenia I , Kaltsas Gregory A , Isidori Andrea M , Akker Scott A , Drake William M , Chew Shern L , Monson John P , Besser G Michael , Grossman Ashley B

Background: Cyclical Cushing’s syndrome has been considered to be a rare clinical entity, characterised by periodic increases in cortisol levels followed by regression of the Cushing’s syndrome. The cycles of hypercortisolism may occur before the establishment of the diagnosis, rendering actual diagnosis difficult, or may occur after inadequate or ineffective treatment and affect disease management. The aim of this study was to investigate the prevalence of cyclicity...

ea0013p132 | Growth and development | SFEBES2007

An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes

David Alessia , Camacho-Hubner Cecilia , Bhangoo Amrit , Rose Stephen , Miraki-Moud Farideh , Akker Scott , Butler Gary , Ten Svetlana , Clayton Peter , Clark Adrian , Savage Martin , Metherell Lou

Inherited growth hormone insensitivity (GHI) is usually caused by mutations in the GH receptor (GHR). Patients present with short stature associated with a mid-facial hypoplasia (Laron facial features) or with normal facial appearance. We previously described an intronic mutation in the GHR gene (A−1 to G−1 substitution in intron 6) resulting in the activation of a pseudoexon (6Ψ) in four related GHI patients with normal facial fea...

ea0056p1160 | Thyroid cancer | ECE2018

Treatment strategies in medullary thyroid carcinoma – outcome following initial surgery with a curative, debulking or prophylactic intent

Mitravela Vasiliki-Ioanna , Glynn Nigel , Waterhouse Mona , Akker Scott , Korbonits Marta , Drake William , Berney Daniel , Plowman Nick , Carpenter Robert , Parvanta Laila , Druce Maralyn

Medullary thyroid carcinoma (MTC) is a rare malignancy which has often metastasised at time of diagnosis. Surgical resection represents the only prospect for cure. However, debulking neck surgery may be beneficial in advanced cases. Prophylactic surgery is increasingly undertaken in asymptomatic patients with known mutations in the RET oncogene. The aim was to describe the outcome following initial surgical treatment for MTC at our institution. We performed a retrospe...

ea0073oc15.4 | Oral Communications 15: Late Breaking | ECE2021

Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy

Gordon Murray B. , Gadelha Monica , Toth Miklos , Doknic Mirjana , Mezosi Emese , Randeva Harpal , Marmon Tonya , Luo Rosa , Monahan Michael , Madan Ajay , Struthers Scott , Krasner Alan

Long-acting somatostatin receptor ligands (LA-SRLs) are a first line medical treatment for acromegaly but require monthly parenteral administration. Paltusotine (CRN00808) is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability (70%), suitable for once daily, oral dosing. The recently reported results of the ACROBAT Edge study (NCT03789656) suggest that patients with acromegaly treated with injected SRLs can switch to once dai...

ea0092ps2-18-04 | Treatment 1 | ETA2023

Comparative effectiveness of selpercatinib vs standard treatment in patients with medullary thyroid cancer: An interpatient analysis from libretto-001

Wirth Lori , Worden Francis , Morris John , Medioni Jacques , Deschler-Baier Barbara , Han Yimei , Kiiskinen Urpo , Jen Min-Hua , Barker Scott , Szymczak Sylwia , Gilligan Adrienne

Objective: Head-to-head data comparing selpercatinib, a highly selective and potent RE arranged during Transfection (RET) kinase inhibitor with CNS activity, to standard treatment of RET-altered medullary thyroid cancer (MTC; cabozantinib or vandetanib) is currently unavailable. This post-hoc comparative effectiveness analysis of data from the phase 1/2 LIBRETTO-001 trial compared investigator-assessed outcomes among patients with RET</e...

ea0098c8 | Clinical – Chemo/SSA/Biologics | NANETS2023

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of oral paltusotine, a small-molecule, selective somatostatin receptor subtype 2 agonist

Luo MS Rosa , Casagrande MD, PhD Alessandra , Oun BA Sonic , Wang MSPH Yang , Scott Struthers PhD R. , Usiskin MD Keith , Krasner MD Alan

Background: Paltusotine is an investigational oral, once-daily, small molecule somatostatin receptor type 2 agonist in development for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.Methods: This multicenter, open-label, phase 1 study enrolled participants with mild, moderate, and severe hepatic impairment based on Child-Pugh classification and matched healthy participants. A single 20-mg oral dose of paltusotine...

ea0098c46 | Clinical – Surgery/Applied Pathology | NANETS2023

Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors

Borbon Luis C. , Sherman Scott K. , Breheny Patrick , Ear Po H. , Menda Yusuf , Chandrasekharan Chandrikha , Bellizzi Andrew M. , O'Dorisio Thomas M. , Dillon Joseph S. , Howe James R

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...

ea0098t2 | Trials In Progress | NANETS2023

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Demeure, MD Michael J. , Cohn, MD Allen L. , Seery, MD Tara , Ding, MS, MA Li , Aziz, MD Usman , Navarro, MD Willis , Paulson, MD Scott

Background: Neuroendocrine tumors (NETs; ~2% of all malignancies) commonly arise from the GI tract, pancreas, and lung and often present with metastatic disease. The PI3K/Akt/mTOR pathway is implicated in the pathogenesis and progression of NETs. The oral mTOR inhibitor (mTORi), everolimus, is approved for treatment of patients with NETs of the GI tract, lung, or pancreas. However, due to the rarity and heterogeneity, nonspecific clinical symptoms, and unique indolent biology,...

ea0077p10 | Adrenal and Cardiovascular | SFEBES2021

Method of venesection and location of peripheral sample alter adrenal venous sampling results and interpretation in primary aldosteronism

Mourougavelou Vishnou , Wu Xilin , Goodchild Emily , Argentesi Giulia , Laycock Kate , Akker Scott , Druce Maralyn , Sze Candy , Waterhouse Mona , Dawnay Anne , Matson Matthew , Brown Morris , Drake William , O’Toole Sam

Introduction: Adrenal venous sampling (AVS) is the criterion standard method of lateralisation in primary aldosteronism (PA). Despite this pivotal role, there is limited consensus and significant variability between centres related to many of the technical aspects of AVS. In this study, we sought to address whether variations in two different technical aspects of AVS altered parameters and interpretation, namely: 1. Peripheral sample site 2. Method of adrenal vein (AV) venesec...